Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
Neoplasms, Glandular and Epithelial
Receptor, Epidermal Growth Factor
Recombinant Fusion Proteins
C225 has dose-dependent pharmacokinetics, and doses that achieve saturation of systemic clearance are well tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.